Key facts
- This page summarizes Dalen Meeter's Form 4 filing for Singular Genomics Systems, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Feb 2025, 18:01.
Dalen Meeter - 09 Feb 2025 Form 4 Insider Report for Singular Genomics Systems, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 09 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Feb 2025, 18:01:25 UTC
- Prior SEC filing
- 17 Dec 2024
- Next SEC filing
- 25 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dalen Meeter
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dalen Meeter filed Form 4 for Singular Genomics Systems, Inc. on 11 Feb 2025.
Change
- Previous filing in this sequence was filed on 17 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OMIC
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +500
- Change %
- +5.6%
- Price
- Shares after
- 9,502
- Date
- 09 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OMIC
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -500
- Change %
- -7.7%
- Price
- Shares after
- 6,000
- Date
- 09 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F3
The RSUs vest in 16 equal quarterly installments over four years measured from February 9, 2024.